ARA-290
EPO derivative targeted for small fiber neuropathy; phase 2 exists for sarcoidosis, not an approved analgesic.
Updated:
Affiliate link to this product’s page on Peptira. We may earn a commission at no extra cost to you. Code KAREL. Disclosure
Quick summary
ARA-290 (cibinetide) is a short peptide inspired by EPO's B-helix. It was designed to signal repair/anti-inflammation via IRR (EPOR-β common) without significantly stimulating erythropoiesis. Most cited for: symptoms and corneal nerve fiber density in small fiber neuropathy associated with sarcoidosis.
Studied for
How it works
Agonism of the innate repair complex → anti-inflammatory and axonal repair pathways in models; minimal hematopoiesis vs EPO.
What the research says
Randomized pilots in sarcoidosis/SFN (Molecular Medicine 2012–2013). Extensions and phase 2b with signals in corneal fiber area and symptoms. No approval; do not extrapolate to generic neuropathies or for “wellness neuroprotection”.
Evidence level
C — small pilot/phase 2 trials; no consolidated phase 3 / approval
What's most reported
- Improvement in neuropathic symptom scores in small studies
- Increase in corneal nerve fiber density/area (biomarker)
- Community: broad neuropathic pain — not demonstrated outside of trial contexts
Common side effects
In trials: generally described as well-tolerated short-term in small populations; the complete post-marketing profile does not exist because there is no approval.
Combines / does not combine
Does not replace management of sarcoidosis/neuropathy by a specialist. No validated stacks.
Frequently asked questions
No. It is structurally related but was designed not to act like classic EPO.
No.
Keep exploring
Keep learning
Related peptides
Educational content. Not medical advice or usage guidelines. Investigational products are not approved medications unless otherwise indicated.